Since the introduction of the first Australian pharmaceoconomic guidelines in 1993, for the pharmaceutical industry to use when preparing a submission for public reimbursement of new drugs, there has been a gradual and accelerating proliferation of pharmacoeconomic guidelines internationally. Viewing the situation in Asia, there is actually a much stronger rationale for introducing and applying pharmacoeconomic evaluation in drug reimbursement decisions. Many Asian countries share the same concerns about high pharmaceutical expenditures and overuse of medicine due to the nature and funding arrangements of the healthcare system.
Journal of Medical Economics Vol. 11, Issue 2, p. 341-343